News
ADXS
0.085
NaN%
--
Weekly Report: what happened at ADXS last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at ADXS last week (1117-1121)?
Weekly Report · 11/24 10:05
Weekly Report: what happened at ADXS last week (1110-1114)?
Weekly Report · 11/17 10:05
Weekly Report: what happened at ADXS last week (1103-1107)?
Weekly Report · 11/10 10:03
Weekly Report: what happened at ADXS last week (1027-1031)?
Weekly Report · 11/03 10:03
Weekly Report: what happened at ADXS last week (1020-1024)?
Weekly Report · 10/27 10:06
Weekly Report: what happened at ADXS last week (1013-1017)?
Weekly Report · 10/20 10:03
Weekly Report: what happened at ADXS last week (1006-1010)?
Weekly Report · 10/13 10:05
Weekly Report: what happened at ADXS last week (0929-1003)?
Weekly Report · 10/06 10:03
Weekly Report: what happened at ADXS last week (0922-0926)?
Weekly Report · 09/29 10:03
Weekly Report: what happened at ADXS last week (0915-0919)?
Weekly Report · 09/22 10:03
Weekly Report: what happened at ADXS last week (0908-0912)?
Weekly Report · 09/15 10:40
Weekly Report: what happened at ADXS last week (0901-0905)?
Weekly Report · 09/08 10:42
Weekly Report: what happened at ADXS last week (0825-0829)?
Weekly Report · 09/01 10:38
Weekly Report: what happened at ADXS last week (0818-0822)?
Weekly Report · 08/25 10:46
Weekly Report: what happened at ADXS last week (0811-0815)?
Weekly Report · 08/18 10:41
Weekly Report: what happened at ADXS last week (0804-0808)?
Weekly Report · 08/11 10:46
Weekly Report: what happened at ADXS last week (0728-0801)?
Weekly Report · 08/04 10:48
Weekly Report: what happened at ADXS last week (0721-0725)?
Weekly Report · 07/28 10:49
Weekly Report: what happened at ADXS last week (0714-0718)?
Weekly Report · 07/21 10:41
More
Webull provides a variety of real-time ADXS stock news. You can receive the latest news about Ayala Pharm through multiple platforms. This information may help you make smarter investment decisions.
About ADXS
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine.